Posted by Michael Wonder on 14 Jul 2022
FDA approves crizotinib for ALK positive inflammatory myofibroblastic tumour
14 July 2022 - On 14 July 2022, the FDA approved crizotinib (Xalkori, Pfizer) for adult and paediatric patients one year of age and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK) positive myofibroblastic tumours.
The safety and efficacy of crizotinib were evaluated in two multicentre, single-arm, open-label trials that included 14 paediatric patients from trial ADVL0912 and 7 adult patients from trial A8081013 with an unresectable, recurrent, or refractory ALK positive myofibroblastic tumour.
